Skip to content
GTN logo — Developing a new drug costs $2.9bn, GTN uses technology to h...

GTN

Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules.

Founded 2017 United Kingdom London, United Kingdom 2-10 employees Seed Total: $2.10M Biotechnology, Quantum +1

General Information

Company Name GTN
Founded Year 2017
Location United Kingdom London, United Kingdom
Employees 2-10
Industries Biotechnology, Quantum, Machine Learning
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with GTN. To contact GTN, visit gtn.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GTN compare?

A PDF of GTN and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GTN soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GTN

GTN: GTN is a biotechnology startup based in the United Kingdom, founded in 2017. The company is focused on revolutionizing drug discovery by leveraging its innovative Generative Tensorial Networks technology. GTN's mission is articulated in its slogan: "Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules." GTN addresses the daunting cost and diminishing productivity of drug development, as it currently averages $2.9 billion for bringing a single novel drug to the market. The company's approach is to utilize a unique blend of machine learning and quantum physics methodologies to simulate, filter, and explore the vast realm of drug-like molecules. This method enables the discovery of previously unknown compounds while significantly reducing development expenses. In 2018, GTN secured a Seed Round investment from Entrepreneur First and Isomer Capital, indicating the support and confidence of established investors in the company's vision and technology. This investment empowers GTN to continue its groundbreaking work in the intersection of biotechnology, quantum, and machine learning.

Business keywords: pharmaceutical research, drug development technology, machine learning in healthcare, quantum physics applications, molecule discovery, innovative drug development, R&D cost reduction, biotechnology innovation

Services & Products

Domain sales
AI technology

Target Customers

Companies looking for AI solutions individuals interested in domain purchase

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round Undisclosed 2
Entrepreneur First, Isomer Capital
01 Nov 2018
Seed Round £2.10M 3
Octopus Ventures, Pentech Ventures +1
04 May 2018
Non Equity Assistance Undisclosed 1
Google for Startups
01 Jun 2017

GTN Alternatives & Competitors

View All Alternatives
GTN vs

Building the algorithmic layer that makes quantum computing useful.

Series B
52 employees
Biotechnology, Life Sciences
GTN vs
AQEMIA
AQEMIA France

Scale drug discovery with quantum-inspired physics and generative AI

87 employees
AI, Biotechnology
GTN vs
BenevolentAI
BenevolentAI United Kingdom

Technology in service of life.

Private Equity
69 employees
AI, Big Data

FAQ About GTN

Developing a new drug costs $2.9bn, GTN uses technology to halve development costs and discover new molecules.
GTN was founded in 2017.
GTN is headquartered in London, United Kingdom.
GTN operates in Biotechnology, Quantum and Machine Learning. Its work centres on pharmaceutical research, drug development technology, machine learning in healthcare and quantum physics applications. Its customers include Companies looking for AI solutions and individuals interested in domain purchase.
GTN has approximately 2-10 employees.
GTN has completed 3 funding rounds, raising a total of $2.10M. The latest funding stage is Seed.
GTN offers: Domain sales, AI technology.
Top alternatives and competitors to GTN include Algorithmiq, AQEMIA, BenevolentAI, Integrated Biosciences, Inc., Atomwise. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GTN and Algorithmiq are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GTN, https://bouncewatch.com/company/gtn, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout